
Kerastem reports positive Phase 2 trial results
US hair loss technology provider Kerastem has confirmed that patients who underwent the Phase 2 clinical trial in early-stage hair loss achieved an increase in mean terminal hair count in men with early hair loss when compared to the control group. Based on these results, Kerastem plans to begin a Phase 3 clinical trial later this year.